Mission
The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against blood cancer. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. The organization has invested nearly $1.7 billion in cutting-edge research and strives to advance breakthroughs in immunotherapy, genomics, and personalized medicine.
Basic Information
Tax-Exempt
Founded in
1949
EIN
13-5644916
Total Assets
$643.9 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 3 of 3 goals
At a Glance
Achieving Breakthroughs Through Research
Powering the scientific engine that drives blood cancer cures and brings hope to patients through groundbreaking research initiatives.
Dare To Dream Project
Transforming pediatric blood cancer treatment and creating a world where every child can survive cancer and thrive in survivorship.
Supporting Survivors
Creating programs that empower survivors to successfully navigate life post-treatment, aiming for optimal quality of life.
Impact Stats
$1.7 billion
Research Funding
Investment in Research
LLS has invested nearly $1.7 billion in blood cancer research, leading to breakthroughs in immunotherapy, genomics, and personalized medicine.
100,000+
Volunteers
Policy and Advocacy
LLS leads a nationwide network of over 100,000 volunteers advocating for policies that remove barriers to care for cancer patients, increase research funding, and improve access to treatments.
Free
Support Services
Patient Support Resources
LLS provides free dynamic and comprehensive support services to help patients navigate their treatment and access quality care.
Past Events
ASCO 2024 Presentation
05/30/2024
Breaking Data Presented at ASCO 2024 showcased the breadth of the Leukemia & Lymphoma Society's Therapy Acceleration Program impact on key blood cancer research.
Impact Reports
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
69
38
/100
Program Expense Ratio
71.78%
8
/20
Program Revenue Growth
-17.82%
2
/20
Leverage Ratio
0.4214
10
/20
Working Capital Ratio
0.965
10
/20
Fundraising Efficiency
2.863
8
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 357.7M | 94.54% |
| Program Services | 9.531M | 2.52% |
| Investment Income | 11.2M | 2.96% |
| Sales of Non-Inventory Assets | 3.933M | 1.04% |
| Other Notable Sources | 0 | 0.00% |
| Total Revenue | 378.3M | 100.00% |
Related Nonprofits
International Cancer Expert Corps Inc.
Health Associations
Cancer OrganizationsPittsburgh Cure Sarcoma
Health Associations
Cancer OrganizationsMichelles Love
Health Associations
Cancer OrganizationsKrabbe Connect
Health Associations
Cancer OrganizationsChildrens Cancer Family Foundation
Health Associations
Cancer Organizations